RESUMEN
OBJECTIVE: This study aimed to describe the type and frequency of enteral and parenteral fluids and medications used during the transport of neonates by a regional pediatric critical care transport team. METHODS: We performed a retrospective analysis of neonates transported by a regional neonatal transport team affiliated with a level IV neonatal intensive care unit within a large care network between 2020 and 2021. Demographic and clinical data were collected from the electronic medical record. Standard frequency tabulation and summary statistics were used to report demographics, transport characteristics, and fluid and medication use; results were then stratified by preterm (37 weeks) and term births. RESULTS: In the 628 included transports, more term than preterm infants received at least 1 fluid or medication (53% vs. 43%, respectively). The most commonly administered medications were antibiotics (ampicillin and gentamicin), prostaglandin, and opiates (morphine sulfate and fentanyl). In addition, term infants received more analgesic medications, antimicrobials, and prostaglandin, whereas preterm infants received total parenteral nutrition more often. There were over 38 different medications provided on the transports studied. CONCLUSION: This study of a single transport team revealed that a wide variety of medications and fluids were used in the transport of neonates, with term infants receiving more medications than preterm infants. These data could be used by transport teams in making or updating their standardized medication lists or in creating simulations.
Asunto(s)
Transporte de Pacientes , Humanos , Recién Nacido , Estudios Retrospectivos , Femenino , Masculino , Cuidados Críticos , Unidades de Cuidado Intensivo Neonatal , Recien Nacido Prematuro , Ambulancias Aéreas , Fluidoterapia/métodos , Antibacterianos/uso terapéuticoRESUMEN
We investigated the epidemiology of the mutant gyrase A gene, a reliable predictor of ciprofloxacin resistance, in Neisseria gonorrhoeae infections at UCLA Health in Los Angeles, California, USA, during November 1, 2015-August 31, 2016. Among 110 patients with N. gonorrhoeae infections, 48 (44%) had the mutant gyrase A gene.
Asunto(s)
Girasa de ADN/genética , Farmacorresistencia Bacteriana/genética , Genotipo , Gonorrea/epidemiología , Neisseria gonorrhoeae/genética , Adolescente , Adulto , Antibacterianos/farmacología , Ciprofloxacina/farmacología , Girasa de ADN/metabolismo , Femenino , Expresión Génica , Gonorrea/diagnóstico , Gonorrea/microbiología , Gonorrea/transmisión , Humanos , Los Angeles/epidemiología , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Epidemiología Molecular , Mutación , Neisseria gonorrhoeae/clasificación , Neisseria gonorrhoeae/aislamiento & purificación , PrevalenciaRESUMEN
Multidrug-resistant Neisseria gonorrhoeae is a top threat to public health. In November 2015, UCLA Health introduced a rapid gyrase A (gyrA) genotypic assay for prediction of Neisseria gonorrhoeae susceptibility to ciprofloxacin. We found a significant reduction in ceftriaxone use with a concomitant increase in targeted therapy.
